Elucidata Corporation partnered with Auron Therapeutics to identify and validate therapeutic targets for Acute Myeloid Leukemia (AML) and eight other oncology indications. The collaboration leveraged Elucidata's data-centric AI Platform to advance Auron's differentiation-based approach to cancer treatment.

The collaboration enabled large-scale integration and analysis of transcriptomic, metabolomic, and epigenetic data alongside patient disease profiles and treatment-response information. This multi-omics framework allowed healthy and diseased cellular states to be characterized at high molecular resolution, revealing actionable biological insights that are difficult to uncover using conventional approaches. Auron contributed rich phenotypic data and multi-omics datasets from hundreds of patient samples. Combined with Polly’s advanced computational methods, this analysis supported the identification and validation of novel therapeutic targets, improved stratification of cancer subtypes, and more precise matching of targets to patient subgroups-laying the foundation for therapies with higher efficacy and fewer side effects.

As an outcome of this collaboration, Elucidata’s target discovery approach helped them assess 10 differentiation targets for Acute Myeloid Leukemia (AML) in just six months, demonstrating its long-term potential. Elucidata’s focused strategy on target, indication, and modalities, leveraging multi-omics data was used to create an advanced knowledge graph for faster summarization, retrieval, and visualization. This approach delivered a comprehensive target-indication assessment report, offering a 360-degree view of targets and disease biology, empowering the company to make data-driven, informed decisions.

Read more in detail: Cancer Novel Target Identified and Advanced to Trials 4× Faster

About Auron Therapeutics

Auron Therapeutics was founded in 2018 to develop therapies that cure cancer by changing the paradigm from cell killing to transforming malignant cells into normal cells. This approach, called differentiation therapy, reactivates cellular programs to drive tumor cell maturation and convert cancer into normal tissue. Its platforms integrate large-omic datasets with miniaturized high-throughput flow cytometry to rapidly identify and validate targets and drugs in primary human patient samples.

About Elucidata Corporation

Founded in 2015, Elucidata is transforming how biological data drives R&D decisions in both academia and industry. Elucidata's cloud based platform Polly optimizes data quality for pre-clinical and clinical drug discovery by harmonizing multi-omics and assay data into ML-ready formats. The platform's harmonization engine is operated by trained experts who curate diverse data types, annotate metadata, and ensure consistent processing at scale.

Polly accommodates more than 25 R&D data types, supporting teams across pre-clinical drug discovery and diagnostics R&D. The platform is trusted by over 25 research organizations, including four of the top ten pharmaceutical companies, to accelerate their discovery programs, and has contributed to more than 40 therapies progressing toward FDA approval. Elucidata has offices in Cambridge, MA, and New Delhi, India.